John Chen, MD PHD

NPI: 1376534552
Total Payments
$204,602
2021 Payments
$27,770
Companies
3
Transactions
95
Medicare Patients
3,132
Medicare Billing
$237,105

Payment Breakdown by Category

Consulting$202,930 (99.2%)
Travel$1,135 (0.6%)
Food & Beverage$462.28 (0.2%)
Research$75.00 (0.0%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $202,930 82 99.2%
Travel and Lodging $1,135 5 0.6%
Food and Beverage $462.28 7 0.2%
Unspecified $75.00 1 0.0%

Payments by Type

General
$204,527
94 transactions
Research
$75.00
1 transactions

Top Paying Companies

Company Total Records Latest Year
Merck Sharp & Dohme LLC $194,930 81 $0 (2021)
Bayer HealthCare Pharmaceuticals Inc. $9,597 13 $0 (2019)
Regeneron Pharmaceuticals, Inc. $75.00 1 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2021 $27,770 30 Merck Sharp & Dohme LLC ($27,770)
2020 $14,435 16 Merck Sharp & Dohme Corporation ($14,435)
2019 $35,322 26 Merck Sharp & Dohme Corporation ($25,650)
2018 $30,825 12 Merck Sharp & Dohme Corporation ($30,825)
2017 $96,250 11 Merck Sharp & Dohme Corporation ($96,250)

All Payment Transactions

95 individual payment records from CMS Open Payments — Page 2 of 4

Date Company Product Nature Form Amount Type
03/31/2021 Merck Sharp & Dohme Corporation LENVIMA (Drug) Consulting Fee Cash or cash equivalent $650.00 General
Category: ONCOLOGY
03/31/2021 Merck Sharp & Dohme LLC Consulting Fee Cash or cash equivalent $300.00 General
Category: ONCOLOGY
03/18/2021 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $850.00 General
Category: ONCOLOGY
03/11/2021 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $290.00 General
Category: ONCOLOGY
02/22/2021 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $485.00 General
Category: ONCOLOGY
12/17/2020 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $455.00 General
Category: ONCOLOGY
12/17/2020 Merck Sharp & Dohme Corporation MK-1454 (Drug) Consulting Fee Cash or cash equivalent $60.00 General
Category: ONCOLOGY
12/10/2020 Merck Sharp & Dohme Corporation LENVIMA (Drug) Consulting Fee Cash or cash equivalent $2,200.00 General
Category: ONCOLOGY
12/10/2020 Merck Sharp & Dohme Corporation MK-1454 (Drug) Consulting Fee Cash or cash equivalent $350.00 General
Category: ONCOLOGY
12/10/2020 Merck Sharp & Dohme Corporation MK-1454 (Drug) Consulting Fee Cash or cash equivalent $60.00 General
Category: ONCOLOGY
11/16/2020 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $1,390.00 General
Category: ONCOLOGY
10/22/2020 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $715.00 General
Category: ONCOLOGY
09/14/2020 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $325.00 General
Category: ONCOLOGY
08/20/2020 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $660.00 General
Category: ONCOLOGY
07/20/2020 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $65.00 General
Category: ONCOLOGY
06/18/2020 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $420.00 General
Category: ONCOLOGY
05/26/2020 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $2,335.00 General
Category: ONCOLOGY
04/23/2020 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $3,745.00 General
Category: ONCOLOGY
03/26/2020 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $160.00 General
Category: ONCOLOGY
02/24/2020 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $65.00 General
Category: ONCOLOGY
01/27/2020 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $1,430.00 General
Category: ONCOLOGY
12/19/2019 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $1,280.00 General
Category: ONCOLOGY
11/27/2019 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $1,110.00 General
Category: ONCOLOGY
10/24/2019 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $1,300.00 General
Category: ONCOLOGY
09/26/2019 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $540.00 General
Category: ONCOLOGY

Research Studies & Clinical Trials

Study Name Company Amount Records
AN EXPLORATORY TUMOR BIOPSY-DRIVEN STUDY TO UNDERSTAND THE RELATIONSHIP BETWEEN BIOMARKERS AND INDICATORS OF CLINICAL RESPONSE IN IMMUNOMODULATORY TREATMENT-NAIVE UNRESECTABLE STAGE III IV MELANOMA PATIENTS RECEIVING REGN2810 ANTI-PD-1 Regeneron Pharmaceuticals, Inc. $75.00 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 10 535 6,624 $290,470 $34,720
2022 16 885 15,656 $688,791 $70,734
2021 14 918 13,417 $620,975 $71,753
2020 10 794 10,345 $467,847 $59,898
Total Patients
3,132
Total Services
46,042
Medicare Billing
$237,105
Procedure Codes
69

All Medicare Procedures & Services

69 procedure records from CMS Medicare Utilization — Page 3 of 3

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
93880 Ultrasound scanning of blood flow (outside the brain) on both sides of head and neck Facility 2021 28 28 $6,552 $933.76 14.3%
93880 Ultrasound scanning of blood flow (outside the brain) on both sides of head and neck Office 2021 18 18 $6,848 $719.37 10.5%
70486 Ct scan of face Facility 2021 14 14 $2,954 $481.36 16.3%
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Office 2021 13 1,149 $1,785 $109.50 6.1%
70553 Mri scan of brain before and after contrast Office 2020 63 65 $215,266 $17,704 8.2%
70450 Ct scan head or brain Facility 2020 278 292 $50,235 $10,004 19.9%
70553 Mri scan of brain before and after contrast Facility 2020 86 88 $44,784 $8,518 19.0%
70498 Ct scan of neck blood vessels with contrast Facility 2020 59 59 $20,882 $4,094 19.6%
70496 Ct scan of blood vessel of head with contrast Facility 2020 55 55 $19,468 $3,956 20.3%
70551 Mri scan brain Facility 2020 59 59 $18,883 $3,623 19.2%
72148 Mri scan of lower spinal canal Office 2020 12 13 $23,784 $2,350 9.9%
70551 Mri scan brain Office 2020 11 11 $22,887 $1,913 8.4%
A9575 Injection, gadoterate meglumine, 0.1 ml Office 2020 59 9,590 $9,590 $1,393 14.5%
72148 Mri scan of lower spinal canal Facility 2020 20 21 $6,732 $1,352 20.1%
70544 Mra scan of head blood vessels Facility 2020 26 26 $6,304 $1,285 20.4%
70450 Ct scan head or brain Office 2020 19 19 $11,926 $1,199 10.1%
93880 Ultrasound scanning of blood flow (outside the brain) on both sides of head and neck Office 2020 12 12 $8,080 $1,030 12.7%
70548 Mra scan of neck blood vessels with contrast Facility 2020 12 12 $3,644 $744.15 20.4%
93880 Ultrasound scanning of blood flow (outside the brain) on both sides of head and neck Facility 2020 23 23 $5,382 $731.76 13.6%

About John Chen, MD PHD

John Chen, MD PHD is a Diagnostic Radiology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1376534552.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, John Chen, MD PHD has received a total of $204,602 in payments from pharmaceutical and medical device companies, with $27,770 received in 2021. These payments were reported across 95 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($202,930).

As a Medicare-enrolled provider, Chen has provided services to 3,132 Medicare beneficiaries, totaling 46,042 services with total Medicare billing of $237,105. Data is available for 4 years (2020–2023), covering 69 distinct procedure/service records.

Practice Information

  • Specialty Diagnostic Radiology
  • Location Boston, MA
  • Active Since 11/04/2005
  • Last Updated 12/14/2023
  • Taxonomy Code 2085R0202X
  • Entity Type Individual
  • NPI Number 1376534552

Products in Payments

  • KEYTRUDA (Biological) $170,865
  • LENVIMA (Drug) $20,040
  • MK-1454 (Drug) $470.00
  • LIBTAYO (Biological) $75.00

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Diagnostic Radiology Doctors in Boston